The Laryngoscope · 2025
NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Minqian, Guan Yingting, Yue Xuejing, Bao Hao, Li Qianwen, Zheng Yiqing, Ou Yongkang, Yang Haidi
Аннотация
OBJECTIVE: The optimal treatment and timing for sudden sensorineural hearing loss (SSNHL) remain debated. This study aimed to determine if the hearing improvement and recovery time were better in the NAD+ group as compared to the control group.
METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups.
RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.030), with greater improvements from 7 days to 3 months post-treatment. Recovery time was shorter in the NAD+ group (62.97 vs. 175.98 days, p = 0.028). Tinnitus and aural fullness improved more in the NAD+ group, especially after 3 months. Higher pre-treatment tinnitus and aural fullness scores were linked to better outcomes with NAD+ for SSNHL.
CONCLUSIONS: NAD+ was more effective in improving hearing and reducing recovery time in SSNHL patients and also benefited tinnitus and aural fullness management.
METHODS: There was a randomized, double-blind, controlled clinical trial conducted between June 2022 and June 2024. SSNHL patients were randomly divided into two groups: the NAD+ group (NAD+ plus standard treatment, n = 18) and the control group (standard treatment, n = 20). The primary outcomes were PTA improvement, recovery rate per Siegel's criteria, and average recovery time, measured from baseline to 3-month follow-ups.
RESULTS: The study with 38 participants (average age 41.74 years, 78.98% male, 42.11% right ear, average Pre-PTA 76.88 dB HL) showed that the NAD+ group experienced significantly greater hearing improvement (40.21 dB HL) compared to the control group (23.06 dB HL, t = 2.722, p = 0.010). The effective rate was higher in the NAD+ group (94.44% vs. 60.00%, Z = -3.014, p = 0.003). Significant group × time interactions were noted in the NAD+ group (F = 2.867, p = 0.030), with greater improvements from 7 days to 3 months post-treatment. Recovery time was shorter in the NAD+ group (62.97 vs. 175.98 days, p = 0.028). Tinnitus and aural fullness improved more in the NAD+ group, especially after 3 months. Higher pre-treatment tinnitus and aural fullness scores were linked to better outcomes with NAD+ for SSNHL.
CONCLUSIONS: NAD+ was more effective in improving hearing and reducing recovery time in SSNHL patients and also benefited tinnitus and aural fullness management.